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Studies on the establishment of the treatment strategy with atovaquone for Babesia gibsoni
infection in dogs 
Babesia gibsoni
Babesia gibsoni infects the red blood cells of dogs and induces hemolytic anemia, jaundice, 
hemoglobinuria, and enlarged spleen. Although diminazene acceturate (DA) has been used to treat acute B. 
gibsoni infections, it often fails to eliminate the parasite from the affected dogs and causes severe adverse 
effects such as pain at the injection site, and nervous symptoms due to cerebral hemorrhage. Some studies 
have reported the effectiveness of new combination therapies such as clindamycin 
(CLDM)-metronidazole-doxycycline (DOXY) or DOXY-enrofloxacine-metronidazole, on experimentally 
infected dogs or clinical patients, but these therapies take a long time to show clinical effectiveness. As 
mentioned above, early treatment is required for acute B. gibsoni infections, but this has a number of 
drawbacks. Atovaquone (ATV) is effective against acute B. gibsoni infections, but ATV monotherapy 
results in relapse as well as the emergence of drug-resistant variants with some single-nucleotide 
polymorphisms (SNPs) in the cytochrome b (cytb). It is necessary to elucidate the relationship between the 
SNPs and ATV resistance.  
 It is required to elucidate relationship between ATV resistance and SNPs in cytb and to develop 
strategies for ATV resistance when ATV would be used for B. gibsoni infection. Therefore, ATV-resistant B. 
gibsoni was developed in vitro and the mitochondrial genes were analyzed. Subsequently the efficacy of 
combination therapy with ATV was evaluated based on pharmacological evaluations using ATV-sensitive 
and ATV-resistant B. gibsoni. 
 In chapter 1, an ATV-resistant B. gibsoni was developed by in vitro exposure of uncloned 
wild-type (WT) B. gibsoni to 800 nM ATV for 6 days. The ATV sensitivity of this parasite was six-fold less 
than that of WT B. gibsoni. Sequence analysis of mitochondrial genes showed a SNP at cytb nt363 (G to T) 
that resulted in the substitution of methionine with isoleucine (M121I). This ATV-resistant B. gibsoni
displayed the same sensitivity as the WT B. gibsoni against 5 drugs, including DA, azithromycin, DOXY, 
CLDM, and proguanil (PG). 
 A tablet formula that combines ATV and PG, Malarone®, is available for treatment of human 
malaria. Nevertheless, the interaction between ATV and PG and the therapeutic efficacy of Malarone®
against canine B. gibsoni infection have not been examined. In chapter 2, the interactions of ATV and PG 
against two in vitro cultures strains of B. gibsoni (WT and ATV-resistant strain) were analyzed by using a 
modified fixed ratio method, and showed synergism. Administration of Malarone® to experimentally B. 
gibsoni infected two dogs in chronic stage and three dogs in acute stage resulted in decreasing parasitemia, 
and clinical improvements were observed. However, all dogs showed relapse of parasitic infection with 
M121I. When the parasites re-increased, the PCV decreased to < 20% in one dog. This dog received the 
second Malarone® treatment, and it was effective as the first treatment. 
 Malarone®, likewise ATV monotherapy, could inhibit B. gibsoni, but this drug could not inhibit 
the reappearance of parasites with the M121I allele. In chapter 3, the efficacy of Malarone® against B. 
gibsoni in acute stage of naturally infected dogs was evaluated. Additionally whether the addition of DOXY 
to Malarone® treatment can inhibit the recurrence and emergence of resistance against ATV or not was 
evaluated. After diagnosis of canine Babesiosis for 8 dogs, the 4 dogs received Malarone® therapy for 10 
days, and another 4 dogs received combination therapy with Malarone® for 10 days and DOXY for 30 days. 
In 3 of 4 cases with Malarone® therapy and in all cases with the DOXY combination, clinical signs and 
anemia improved soon after initiation of the treatment. One dog developed anemia, although parasitemia 
decreased during Malarone® therapy. Two of 4 dogs with DOXY combination did not relapse, owhereas, 
other 3 dogs with Malarone® therapy and 2 dogs with DOXY combination relapsed during observation 
period. These 5 relapsed dogs received second Malarone® therapy and they responded well. However, one 
dog relapsed again after the second treatment. This dog received third Malarone® administration but had a 
progression of anemia. Real-time PCR assays showed under 0.1% in all dogs at the start of Malarone®
administration, but relapsed dogs showed 15-96% of M121I population at the initiation of the second 
treatment. 
 In this study, the new therapeutic strategy was tried for experimentally or naturally infected dogs, 
based on the date from in vitro study. The ATV-resistant B. gibsoni isolated in this study could be useful for 
further research, not only in developing a treatment strategy against the emergence of ATV resistance, but 
also for studying the mechanism of action of ATV against B. gibsoni. The in vivo study suggested that 
combination with ATV, PG and DOXY might be effective for canine Babesiosis, although even this 
combination could not eliminate the parasites from host completely. The further detailed studies about 
mechanism of ATV against B. gibsoni are required.  


